Show simple item record

dc.contributor.authorKarunamuni, RA
dc.contributor.authorHuynh-Le, M-P
dc.contributor.authorFan, CC
dc.contributor.authorThompson, W
dc.contributor.authorLui, A
dc.contributor.authorMartinez, ME
dc.contributor.authorRose, BS
dc.contributor.authorMahal, B
dc.contributor.authorEeles, RA
dc.contributor.authorKote-Jarai, Z
dc.contributor.authorMuir, K
dc.contributor.authorLophatananon, A
dc.contributor.authorUKGPCS Collaborators,
dc.contributor.authorTangen, CM
dc.contributor.authorGoodman, PJ
dc.contributor.authorThompson, IM
dc.contributor.authorBlot, WJ
dc.contributor.authorZheng, W
dc.contributor.authorKibel, AS
dc.contributor.authorDrake, BF
dc.contributor.authorCussenot, O
dc.contributor.authorCancel-Tassin, G
dc.contributor.authorMenegaux, F
dc.contributor.authorTruong, T
dc.contributor.authorPark, JY
dc.contributor.authorLin, H-Y
dc.contributor.authorTaylor, JA
dc.contributor.authorBensen, JT
dc.contributor.authorMohler, JL
dc.contributor.authorFontham, ETH
dc.contributor.authorMultigner, L
dc.contributor.authorBlanchet, P
dc.contributor.authorBrureau, L
dc.contributor.authorRomana, M
dc.contributor.authorLeach, RJ
dc.contributor.authorJohn, EM
dc.contributor.authorFowke, JH
dc.contributor.authorBush, WS
dc.contributor.authorAldrich, MC
dc.contributor.authorCrawford, DC
dc.contributor.authorCullen, J
dc.contributor.authorPetrovics, G
dc.contributor.authorParent, M-É
dc.contributor.authorHu, JJ
dc.contributor.authorSanderson, M
dc.contributor.authorPRACTICAL Consortium,
dc.contributor.authorMills, IG
dc.contributor.authorAndreassen, OA
dc.contributor.authorDale, AM
dc.contributor.authorSeibert, TM
dc.date.accessioned2022-01-25T11:35:13Z
dc.date.available2022-01-25T11:35:13Z
dc.date.issued2021-06-14
dc.identifier.citationProstate cancer and prostatic diseases, 2021
dc.identifier.issn1365-7852
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4969
dc.identifier.eissn1476-5608
dc.identifier.eissn1476-5608
dc.identifier.doi10.1038/s41391-021-00403-7
dc.identifier.doi10.1038/s41391-021-00403-7
dc.description.abstractBACKGROUND: We previously developed an African-ancestry-specific polygenic hazard score (PHS46+African) that substantially improved prostate cancer risk stratification in men with African ancestry. The model consists of 46 SNPs identified in Europeans and 3 SNPs from 8q24 shown to improve model performance in Africans. Herein, we used principal component (PC) analysis to uncover subpopulations of men with African ancestry for whom the utility of PHS46+African may differ. MATERIALS AND METHODS: Genotypic data were obtained from the PRACTICAL consortium for 6253 men with African genetic ancestry. Genetic variation in a window spanning 3 African-specific 8q24 SNPs was estimated using 93 PCs. A Cox proportional hazards framework was used to identify the pair of PCs most strongly associated with the performance of PHS46+African. A calibration factor (CF) was formulated using Cox coefficients to quantify the extent to which the performance of PHS46+African varies with PC. RESULTS: CF of PHS46+African was strongly associated with the first and twentieth PCs. Predicted CF ranged from 0.41 to 2.94, suggesting that PHS46+African may be up to 7 times more beneficial to some African men than others. The explained relative risk for PHS46+African varied from 3.6% to 9.9% for individuals with low and high CF values, respectively. By cross-referencing our data set with 1000 Genomes, we identified significant associations between continental and calibration groupings. CONCLUSION: We identified PCs within 8q24 that were strongly associated with the performance of PHS46+African. Further research to improve the clinical utility of polygenic risk scores (or models) is needed to improve health outcomes for men of African ancestry.
dc.formatPrint-Electronic
dc.languageeng
dc.language.isoeng
dc.publisherSPRINGERNATURE
dc.rights.urihttp://www.rioxx.net/licenses/all-rights-reserved
dc.subjectUKGPCS Collaborators
dc.subjectPRACTICAL Consortium
dc.titlePerformance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24.
dc.typeJournal Article
dcterms.dateAccepted2021-05-27
rioxxterms.versionAM
rioxxterms.versionofrecord10.1038/s41391-021-00403-7
rioxxterms.licenseref.startdate2021-06-14
dc.relation.isPartOfProstate cancer and prostatic diseases
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.publication-statusPublished
pubs.embargo.termsNot known
icr.researchteamOncogenetics
dc.contributor.icrauthorEeles, Rosalind
dc.contributor.icrauthorKote-Jarai, Zsofia


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record